A randomized clinical trial of nicotine lozenge for smokeless tobacco use

Nicotine and Tobacco Research

Volumn 11, Issue 12, 2009, Pages 1415-1423

  Ebbert, Jon O ^a   Severson, Herbert H ^b   Croghan, Ivana T ^a   Danaher, Brian G ^b   Schroeder, Darrell R ^a  

^a Mayo Clinic   (United States)

^b OREGON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; LOZENGE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SMOKELESS TOBACCO; SMOKING CESSATION; THERAPY EFFECT; TIME; TREATMENT DURATION; WITHDRAWAL SYNDROME;

ADMINISTRATION, ORAL; ADULT; AFFECT; ATTENTION; DOSAGE FORMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; POLYMETHACRYLIC ACIDS; POLYVINYLS; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 70849116201     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntp154     Document Type: Article

References (33)

1. Benowitz, N. L., Ahijevych, K., Hall, S., Hansson, A., Henningfield, J., Hurt, R. D., et al. (2002). Biochemical verifi cation of tobacco use and cessation. Nicotine & Tobacco Research, 4, 149-159.
2. Benowitz, N. L., Porchet, H., Sheiner, L., & Jacob, P., 3rd. (1988). Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gum. Clinical Pharmacology and Therapeutics, 44, 23-28.
3. Boyle, R. G. (1992). Smokeless tobacco cessation with nicotine replacement: A randomized clinical trial. Dissertation Abstracts International, 54(3-A), 825.
4. Choi, J. H., Dresler, C. M., Norton, M. R., & Strahs, K. R. (2003). Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine & Tobacco Research, 5, 635-644.
5. Dale, L. C., Ebbert, J. O., Glover, E. D., Croghan, I. T., Schroeder, D. R., Severson, H. H., et al. (2007). Bupropion SR for the treatment of smokeless tobacco use. Drug and Alcohol Dependence, 90, 56-63.
6. Ebbert, J. O., Carr, A. B., & Dale, L. C. (2004). Smokeless tobacco: An emerging addiction. Medical Clinics of North America, 88, 1593-1605.
7. Ebbert, J. O., Dale, L. C., Severson, H. H., Croghan, I. T., Rasmussen, D. F., Schroeder, D. R., et al. (2007). Nicotine lozenges for the treatment of smokeless tobacco use. Nicotine & Tobacco Research, 9 233-240.
8. Ebbert, J. O., Montori, V., Vickers, K. S., Erwin, P. C., Dale, L. C., & Stead, L. F. (2007). Interventions for smokeless tobacco use cessation. Cochrane Database of Systemic Reviews, (4) CD004306.
9. Ebbert, J. O., Patten, C. A., & Schroeder, D. R. (2 006). The Fagerström Test for Nicotine Dependence-Smokeless Tobacco (FTND-ST). Addictive Behaviors, 31 (9), 1716-1721.
10. Ebbert, J. O., Post, J. A., Moyer, T. P., Dale, L. C., Schroeder, D. R., & Hurt, R. D. (2007). Nicotine percentage replacement among smokeless tobacco users with nicotine patch. Drug and Alcohol Dependence, 89 (2-3), 223-226.
11. Fisher, M. A., Taylor, G. W., & Tilashalski, K. R. (2005). Smoke-less tobacco and severe active periodontal disease, NHANES III. Journal of Dental Research, 84, 705-710.
12. Hatsukami, D. K., Grillo, M., Boyle, R., Allen, S., Jensen, J., Bliss, R., et al. (2000). Treatment of spit tobacco users with transdermal nicotine system and mint snuff. Journal of Consulting and Clinical Psychology, 68, 241-249.
13. Hatsukami, D. K., Jensen, J., Allen, S., Grillo, M., & Bliss, R. (1996). Effects of behavioral and pharmacological treatment on smokeless tobacco users. Journal of Consulting and Clinical Psychology, 64, 153-161.
14. Henley, S. J., Thun, M. J., Connell, C., & Calle, E. E. (2005). Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes and Control, 16, 347-358.
15. Howard-Pitney, B., Killen, J. D., & Fortmann, S. P. (1999). Quitting chew: Results from a randomized trail using nicotine patches. Experimental and Clinical Psychopharmacology, 7, 362-371.
16. Hughes, J. R. (1998). Errors in using tobacco withdrawal scale [Letter to editor]. Tobacco Control, 7, 92-93.
17. Hughes, J. R., & Hatsukami, D. (1986). Signs and symptoms of tobacco withdrawal. Archives of General Psychiatry, 43, 289-294.
18. Hughes, J. R., Keely, J. P., Niaura, R. S., Ossip-Klein, D. J., Richmond, R. L., & S wan, G. E. (2003). Measures of abstinence in clinical trials: Issues and recommendations. Nicotine & Tobacco Research, 5, 13-25.
19. Jacob, P., Hatsukami, D., Severson, H., Hall, S., Yu, L., & Benowitz, N. L. (2002). Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. Cancer Epidemiology, Biomarkers and Prevention, 11, 1668-1673.
20. Jacob, P., Yu, L., Shulgin, A. T., & Benowitz, N. L. (1999). Minor tobacco alkaloids as biomarkers for tobacco use: Comparison of users of cigarettes, smokeless tobacco, cigars, and pipes. American Journal of Public Health, 89, 731-736.
21. Moyer, T. P., Charlson, J. R., Enger, R. J., Dale, L. C., Ebbert, J. O., Schroeder, D. R., et al. (2002). Simultaneous analysis of nicotine, nicotine metabolites, and tobacco alkaloids in serum or urine by tandem mass spectrometry, with clinically relevant metabolic profiles. Clinical Chemistry, 48, 1460-1471.
22. Muscat, J. E., Hoffmann, D., & Wynder, E. L. (1995). The epidemiology of renal cell carcinoma. A second look. Cancer, 75, 2552-2557.
23. Muscat, J. E., Stellman, S. D., Hoffmann, D., & Wynder, E. L. (1997). Smoking and pancreatic cancer in men and women. Cancer Epidemiology, Biomarkers and Prevention, 6, 15-19.
24. Radloff, L. S. (1977). The CES-D scale: A self-report depression scale for research in the general population. Applied Psychological Measurement, 1, 385-401.
25. Severson, H. H. (1992). Enough snuff: ST cessation from the behavioral, clinical, and public health perspectives (NIH Publication No. 93-3461). Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, September 1992.
26. Severson, H. H. (1999). Enough snuff: A guide for quitting smokeless tobacco (5th ed.). Eugene, OR: Applied Behavior Science Press.
27. Severson, H. H. (2003). What have we learned from 20 years of research on smokeless tobacco cessation? American Journal of the Medical Sciences, 326, 206-211.
28. Severson, H. H., Akers, L., Boles, S. M., Andrews, J. A., & Yovanoff, P. (2004). Development of a brief smokeless tobacco dependence scale. Paper presented at the Society for Nicotine and Tobacco Research, Prague.
29. Shiffman, S. (2005). Nicotine lozenge efficacy in light smokers. Drug and Alcohol Dependence, 77, 311-314.
30. Shiffman, S., Dresler, C. M., Hajek, P., Gilburt, S. J., Targett, D. A., & Strahs, K. R. (2002). Efficacy of a nicotine lozenge for smoking cessation. Archives of Internal Medicine, 162, 1267-1276.
31. Stepanov, I., Jensen, J., Hatsukami, D., & Hecht, S. S. (2008). New and traditional smokeless tobacco: Comparison of toxicant and carcinogen levels. Nicotine & Tobacco Research, 10, 1773-1782.
32. Stockwell, H. G., & Lyman, G. H. (1986). Impact of smoking and smokeless tobacco on the risk of cancer of the head and neck. Head and Neck Surgery, 9, 104-110.
33. Substance Abuse and Mental Health Services Administration. (2007). Results from the 2006 National Survey on Drug Use and Health: National findings (NSDUH Series H-32, DHHS Publication No. SMA 07-4293). Rockville, MD: Office of Applied Studies.